This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
by Zacks Equity Research
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
LQDAPositive Net Change IMCRNegative Net Change INDVNegative Net Change SYRENegative Net Change
biotechs
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
by Zacks Equity Research
TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.
TGTXPositive Net Change LQDAPositive Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
by Zacks Equity Research
ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, despite meeting its primary efficacy goal.
RHHBYNegative Net Change ADCTNegative Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
by Zacks Equity Research
KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a nearly $1B cash pile fuels confidence.
KRYSPositive Net Change LQDAPositive Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?
by Sundeep Ganoria
AbbVie's FDA approval of Decnupaz for BPDCN marks its first blood cancer ADC and expands a strategy built on deals and internal development.
AZNNegative Net Change PFENegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
by Kanishka Das
OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.
BIIBNegative Net Change RGNXPositive Net Change OCGNNegative Net Change
biotechs
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
by Kanishka Das
Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.
BIIBNegative Net Change ALPMYPositive Net Change OCGNNegative Net Change
biotechs
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028
by Kanishka Das
Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.
LLYPositive Net Change RGNXPositive Net Change OCGNNegative Net Change
biotechs
GILD Reports Positive Results From Late-Stage Liver Disease Study
by Zacks Equity Research
Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.
GSKNegative Net Change GILDNegative Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
by Zacks Equity Research
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
LQDAPositive Net Change FULCNegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals